enfortumab vedotin,nivolumab
astellas,bms,seagen
[' ev ', 'nivo']
nivo-ice in high risk pts. 1st rel chl 100% orr, 89% crr 10mo med fu post asct, v high pfs so far 14% engraftment syndrome in subseq asct (lower than other reports ? due to diff definitions) more ev that pd1 prior to asct maybe beneficial #ash22 
Associate Professor of Haematology and lymphoma specialist at Oxford Cancer and Haematology centre. Christian, husband and father.